Aurobindo Pharma gets USFDA nod for Repaglinide tablets

Aurobindo Pharma has received final approval from the US Food & Drug Administration to

RELATED ARTICLES

manufacture and market generic Repaglinide tablets that are used as an adjunct to diet in diabetic patients.

The approval is for multiple strengths of the drug in 0.5mg, 1mg and 2mg. The product is ready for launch, the company said in a statement.

The Repaglinide tablets are the generic equivalent of Novo Nordisk Prandin Tablets. These are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, it added.

Quoting IMS data, the company said the market size of the product is estimated to be USD 274 million for the twelve months ending November 2013.

Aurobindo now has a total of 189 abbreviated new drug approvals from USFDA.

Shares of Aurobindo Pharma were trading at Rs 433 per scrip in the afternoon trade, down 0.74 per cent from previous close, on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Copy the characters (respecting upper/lower case) from the image.

EDITORIAL OF THE DAY

  • Government must give up majority ownership in loss making PSU banks

    After four years of braving economic slowdown and provisioning for rising non performing assets (NPAs), public sector banks are in urgent of capital.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

BK Chaturvedi

Cooperative federalism and governance

Improving relations between the states and the Centre to improve ...

Kuruvilla Pandikattu SJ

Reason drives religion, science

Both religion and science are driven by reason, claims Rama ...

Gautam Gupta

Retailers have it tough, thanks to e-commerce

For the past few months our focus has been on ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture